Breast cancer stage strongly linked to development of AF; new-onset AF after breast cancer diagnosis linked to increased cardiovascular mortality
TUESDAY, Nov. 23, 2021 (HealthDay News) — The incidence of atrial fibrillation (AF) is significantly increased after breast cancer diagnosis, according to a study published online Nov. 14 in the European Heart Journal.
Avirup Guha, M.B.B.S., M.P.H., from the Case Western Reserve University in Cleveland, and colleagues identified women ages 66 years and older with a new primary diagnosis of breast cancer from 2007 through 2014 from the Surveillance, Epidemiology, and End Results-Medicare-linked database. These 85,423 patients were matched to Medicare enrollees without cancer in a 1:1 ratio and were followed for one year for a primary outcome of AF.
The researchers found that 11 percent of the breast cancer patients had an AF diagnosis prior to diagnosis of breast cancer. In a one-year period after breast cancer diagnosis, 3.9 percent of patients had a diagnosis of new-onset AF (incidence, 3.3 percent at one year). In contrast, the incidence of new-onset AF was 1.8 percent in matched noncancer controls. Breast cancer stage was strongly associated with development of AF, apart from traditional demographic and cardiovascular risk factors (American Joint Committee on Cancer Stage II/III/IV versus I: adjusted hazard ratios, 1.51, 2.63, and 4.21, respectively). Increased one-year cardiovascular mortality was seen in association with new-onset AF after breast cancer diagnosis (adjusted hazard ratio, 3.00).
“The two most stark findings are that atrial fibrillation after breast cancer diagnosis increases deaths from heart and blood vessel problems, and that cancer severity is a strong risk factor for the development of atrial fibrillation,” Guha said in a statement.
One author disclosed financial ties to the pharmaceutical and medical device industries.
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
Central Adiposity Reclassifies Cardiovascular Risk Across BMI Spectrum
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer
High-Dose Omega-3 Linked to A-Fib Risk in Patients With High CVD Risk
Physical Activity Reduces Stroke, Mortality, Regardless of A-Fib
AHA: Consuming Up to 400 mg/Day of Caffeine Safe for Most Adults
Global Findings Indicate Breast Cancer and A-Fib Incidence Frequently Overlap
Docosahexaenoic Acid Supplement Does Not Improve Cognitive Performance